Since March 2014, US investors have been able to trade NeuroVive shares online on the OTC market. The shares became quoted on the Pink Market in June 2015. The subsequent upgrade to OTCQX represents a further seal of approval as there are increased regulatory requirements that enable trading and companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications.
The upgrade is a part of NeuroVive’s strategic focus on increasing its presence in the US and raising awareness of the company amongst investors and potential partners. NeuroVive’s current projects include a pre-clinical study in traumatic brain injury (TBI) alongside prestigious University of Pennsylvania (PENN).
“US interest in NeuroVive has increased in recent years, and we believe that the upgrade to OTCQX will help to accelerate this trend as we move forward. Awareness of the company is likely to increase further in the US as our development programs progress, including those carried out alongside US partners. It’s important to have a presence on a credible and well-functioning trading platform in order to convert that interest into strengthening our international ownership structure,” commented NeuroVive’s CEO Erik Kinnman.
The NeuroVive share is registered with OTC’s reporting service for foreign securities in New York under the ticker symbol NEVPF:US. NEVPF’s share price can be monitored at www.otcmarkets.com or through US brokers.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, we connect a diverse network of broker-dealers that provide liquidity and execution services. We enable investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors. To learn more about how we create better informed and more efficient markets, visit www.otcmarkets.com
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
About OTCQX International
The OTCQX Best Market is for established, global and growth companies, operated by OTC Markets Group. To qualify for the OTCQX Best Market, companies must meet high financial standards, demonstrate compliance with U.S. securities laws, be current in their disclosure, and be sponsored by a professional third-party advisor. The companies found on OTCQX are distinguished by the integrity of their operations and diligence with which they convey their qualifications. For more information, please visit www.otcmarkets.com.
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq, Stockholm, Sweden.
For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)46 275 62 21 or firstname.lastname@example.org
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on the 2 June 2016, at 13.00 CET.